BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Job Trends

  2018 Report From California Life Sciences Association, PwC Details New Peaks for Life Sciences Industry in California

  The 2018 report shows that California continues to outpace other states in life science-related economic growth, including venture funding, and NIH funding.

  November 15, 2017

   · 

  8 min read
• Drug Development

  ITM’s Successful Hosting of the Investigator Meeting for Phase III Clinical Trial COMPETE With n.c.a.177Lu-Edotreotide (Solucin) in Cancer Patients With GEP-NET

  ITM’s subsidiary ITM Solucin lead 2-day-event focused on study update and efficient trial execution.

  November 15, 2017

   · 

  2 min read
• Business

  Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo’s FDA-Approved Human Prescription Drug

  Napo’s HIV Scientific Advisory Board will focus primarily on physician education, and community and global awareness regarding the importance and availability of solutions for neglected comorbidities.

  November 15, 2017

   · 

  8 min read
• Lone Star Bio

  iReliev Introduces FDA Cleared Therapeutic Wearable Therapy System Approved for Arthritis

  The company’s line of iReliev brand products offer consumers FDA cleared tools for non-invasive, drug-free pain relief and muscle conditioning.

  November 15, 2017

   · 

  2 min read
• Pharm Country

  Tauriga Sciences Focused on Consummating Significant Transactions to Build Long Term Shareholder Value

  Tauriga Sciences engaged in the building of life sciences businesses and technologies, today announced its intention to consummate one or more significant acquisition and/or licensing transactions during the calendar year 2018 to both restore and create long term shareholder value.

  November 15, 2017

   · 

  4 min read
• Trillium Announces Private Placement

  Trillium today announced that it has entered into subscription agreements for the sale of 1,950,000 common shares and 400,000 Series II non-voting convertible first preferred shares at a price of U.S.$8.50 per share, in a non-brokered private placement for gross proceeds of U.S.$19,975,000.

  November 15, 2017

   · 

  4 min read
• Drug Development

  CRF Health’s TrialMax Touch Selected by Leading Specialty Pharmaceutical Company for Pediatric Rare Disease Phase II Study

  CRF Health has been selected by a leading specialty pharmaceutical company for its latest pediatric rare disease Phase II study.

  November 15, 2017

   · 

  2 min read
• Business

  Agenus Receives License Fee of $4M USD From Merck

  As previously announced, Merck is responsible for all future product development expenses for the selected antibody and Agenus is eligible to receive up to an additional $99M in milestone payments, as well as royalties on worldwide product sales.

  November 15, 2017

   · 

  2 min read
• BioCapital

  Aziyo Presents Positive Initial Data From Clinical Study of Biologic Extracellular Matrix Scaffold for Femoral Arterial Reconstruction

  There were no device-related adverse events or infections and primary patency was maintained in 97.6% of procedures.

  November 15, 2017

   · 

  3 min read
• Pharmalink is Renamed Calliditas Therapeutics

  The Swedish Companies Registration Office has approved and registered the company’s change of name from Pharmalink AB to Calliditas Therapeutics AB.

  November 15, 2017

   · 

  1 min read